SYNGENE SYNTACS
LIVE

Serial Number

98092301

Owner

SYNGENE INTERNATIONAL LIMITED

Attorney

THOMAS J. MANGO

First Use Date

Mar 31, 2022

Filing Date

Jul 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SYNGENE SYNTACS Trademark

Serial Number: 98092301 • Registration: 8368790

SYNGENE SYNTACS is a trademark filed by SYNGENE INTERNATIONAL LIMITED on July 19, 2023. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

SYNGENE INTERNATIONAL LIMITED (13 trademarks)

Biocon Special Economic Zone,Biocon Park
Link Rd, Bangalore Karnataka , IN

Entity Type: 03

Trademark Details

Filing Date

July 19, 2023

Registration Date

July 28, 2026

First Use Anywhere

March 31, 2022

First Use in Commerce

March 31, 2022

Published for Opposition

December 3, 2024

Goods & Services

Scientific research and custom synthesis in the nature of chemical engineering; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing of materials; laboratory testing services for research purposes; testing of pharmaceuticals; chemical engineering; chemical analysis; drug discovery services; pharmaceutical drug development services; pharmaceutical product development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of companion animals, commercial livestock and wild animals; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; scientific research in the nature of conducting clinical trials for others in the field of chemical engineering; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific research services relating to the isolation and cultivation of human tissues and cells; preparation of reports relating to scientific and technical research; biochemical analysis in the field of molecular biology; contract scientific research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific laboratory services; services of a chemical or biological scientific laboratory; laboratory research services relating to pharmaceuticals; scientific research and development and scientific research consultation in the fields of antibodies, antibody technology, chemistry, bioinformatics, biomedical, biologics, biotechnology, bio therapeutics, biology, biochemical, cell line, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymer, peptide synthesis, protein, solid state characterization; toxicokinetic, scientific and technological services, namely, scientific research, development, design, testing, and engineering in the fields of antibody, API, biomolecules, cell bank characterization, chiral, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nano particle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applications and none of the aforesaid services in the field of agriculture, horticulture and forestry

Treatment of materials by polymerization; custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, medicines, drugs by pharmaceutical compounders; contract manufacturing in the field of pharmaceuticals and drug development

Business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis applications

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 28, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 28, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jul 6, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 6, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jun 16, 2026 SUPC
USE AMENDMENT FILED
Mar 9, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Mar 9, 2026 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 9, 2025 NOAM
TTAB RELEASE CASE TO TRADEMARKS
Jul 31, 2025 TMBN
OPPOSITION TERMINATED NO. 999999
Jul 31, 2025 OP.T
OPPOSITION DISMISSED NO. 999999
Jul 31, 2025 OP.D
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 1, 2025 ETOP
OPPOSITION INSTITUTED NO. 999999
May 28, 2025 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Dec 16, 2024 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 6, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 5, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 5, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 27, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 27, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 27, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 27, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 27, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 27, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 25, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 17, 2023 NWOS
NEW APPLICATION ENTERED
Jul 22, 2023 NWAP